Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.65 |
| ▸ | SELL | P14151 | 1/20 | 0.65 |
| ▸ | MAG | P20916 | 7/20 | 0.61 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.57 |
| ▸ | SELE | P16581 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14648686 | 1.00 | SELP (0.65) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL16185999 | 0.96 | SELP (0.64) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL16188535 | 0.94 | SELP (0.62) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL29391699 | 0.91 | SELP (0.73) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL29389517 | 0.91 | SELP (0.73) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL29448496 | 0.91 | SELP (0.73) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL29405702 | 0.91 | SELP (0.73) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL13195877 | 0.91 | SELP (0.73) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL29372449 | 0.91 | SELP (0.73) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL13978771 | 0.91 | SELP (0.73) | SELPSELLMAGSIGLEC7SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246221-A1 | CHIMERIC ANTIGEN RECEPTOR TARGETING SIALYL LEWIS A AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210236554-A1 | LOW DOSE RADIATION CONDITIONING FOR IMMUNOTHERAPY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246221-A1 | CHIMERIC ANTIGEN RECEPTOR TARGETING SIALYL LEWIS A AND USES THEREOF | SIGLEC9, SIGLEC7, FCGR2A | SELP 123/4885SELL 72/4885MAG 451/4885 |
| US-20210236554-A1 | LOW DOSE RADIATION CONDITIONING FOR IMMUNOTHERAPY | TNFRSF9, HAVCR2, ICOS | SELP 647/4885SELL 590/4885MAG 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.